166 related articles for article (PubMed ID: 1740460)
1. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain.
Ortel TL; Devore-Carter D; Quinn-Allen M; Kane WH
J Biol Chem; 1992 Feb; 267(6):4189-98. PubMed ID: 1740460
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.
Ortel TL; Quinn-Allen MA; Charles LA; Devore-Carter D; Kane WH
J Clin Invest; 1992 Dec; 90(6):2340-7. PubMed ID: 1281831
[TBL] [Abstract][Full Text] [Related]
3. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region.
Kane WH; Devore-Carter D; Ortel TL
Biochemistry; 1990 Jul; 29(29):6762-8. PubMed ID: 2397212
[TBL] [Abstract][Full Text] [Related]
4. A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex.
Majumder R; Quinn-Allen MA; Kane WH; Lentz BR
Blood; 2008 Oct; 112(7):2795-802. PubMed ID: 18587009
[TBL] [Abstract][Full Text] [Related]
5. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis.
Kim SW; Quinn-Allen MA; Camp JT; Macedo-Ribeiro S; Fuentes-Prior P; Bode W; Kane WH
Biochemistry; 2000 Feb; 39(8):1951-8. PubMed ID: 10684644
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
Camire RM; Kalafatis M; Tracy PB
Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
[TBL] [Abstract][Full Text] [Related]
7. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.
Kim SW; Ortel TL; Quinn-Allen MA; Yoo L; Worfolk L; Zhai X; Lentz BR; Kane WH
Biochemistry; 1999 Aug; 38(35):11448-54. PubMed ID: 10471296
[TBL] [Abstract][Full Text] [Related]
8. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
Thorelli E; Kaufman RJ; Dahlbäck B
J Biol Chem; 1998 Jun; 273(26):16140-5. PubMed ID: 9632668
[TBL] [Abstract][Full Text] [Related]
9. The phosphatidylserine binding site of the factor Va C2 domain accounts for membrane binding but does not contribute to the assembly or activity of a human factor Xa-factor Va complex.
Majumder R; Quinn-Allen MA; Kane WH; Lentz BR
Biochemistry; 2005 Jan; 44(2):711-8. PubMed ID: 15641797
[TBL] [Abstract][Full Text] [Related]
10. The factor V B-domain provides two functions to facilitate thrombin cleavage and release of the light chain.
Marquette KA; Pittman DD; Kaufman RJ
Blood; 1995 Oct; 86(8):3026-34. PubMed ID: 7579396
[TBL] [Abstract][Full Text] [Related]
11. Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex.
Nicolaes GA; Villoutreix BO; Dahlbäck B
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):89-100. PubMed ID: 10691103
[TBL] [Abstract][Full Text] [Related]
12. Activation of bovine factor V by an activator purified from the venom of Naja naja oxiana.
Gerads I; Tans G; Yukelson LYa ; Zwaal RF; Rosing J
Toxicon; 1992 Sep; 30(9):1065-79. PubMed ID: 1440644
[TBL] [Abstract][Full Text] [Related]
13. Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.
Gilbert GE; Novakovic VA; Kaufman RJ; Miao H; Pipe SW
Blood; 2012 Aug; 120(9):1923-32. PubMed ID: 22613792
[TBL] [Abstract][Full Text] [Related]
14. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.
Lewis DA; Moore KD; Ortel TL
Blood Coagul Fibrinolysis; 2003 Jun; 14(4):361-8. PubMed ID: 12945878
[TBL] [Abstract][Full Text] [Related]
15. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.
Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
Blood; 1990 May; 75(10):1999-2004. PubMed ID: 2110840
[TBL] [Abstract][Full Text] [Related]
16. Identification of the MMRN1 binding region within the C2 domain of human factor V.
Jeimy SB; Woram RA; Fuller N; Quinn-Allen MA; Nicolaes GA; Dahlbäck B; Kane WH; Hayward CP
J Biol Chem; 2004 Dec; 279(49):51466-71. PubMed ID: 15452129
[TBL] [Abstract][Full Text] [Related]
17. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.
Ortel TL; Quinn-Allen MA; Keller FG; Peterson JA; Larocca D; Kane WH
J Biol Chem; 1994 Jun; 269(22):15898-905. PubMed ID: 7515064
[TBL] [Abstract][Full Text] [Related]
18. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
Monteiro RQ; Zingali RB
Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
[TBL] [Abstract][Full Text] [Related]
19. The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis.
Saleh M; Peng W; Quinn-Allen MA; Macedo-Ribeiro S; Fuentes-Prior P; Bode W; Kane WH
Thromb Haemost; 2004 Jan; 91(1):16-27. PubMed ID: 14691564
[TBL] [Abstract][Full Text] [Related]
20. Role of the B domain for factor VIII and factor V expression and function.
Pittman DD; Marquette KA; Kaufman RJ
Blood; 1994 Dec; 84(12):4214-25. PubMed ID: 7994036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
